---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-002378"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2025-07-14T23:59:59+00:00"
generated_at: "2026-05-18T06:47:14.523239+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Silexion shareholders approve 1-for-15 reverse split and board election

## Summary
- Reverse share split at 1-for-15 ratio approved with 59.6% of votes in favor.
- Equity incentive plan shares increased by 1,271,859 to 1,428,268 total.
- All seven director nominees elected; Ruth Alon (68.2%) and Ilan Levin (68.1%) received lowest support.
- Ratification of Kesselman & Kesselman (PwC) as auditors approved with 98.3% in favor.
- Meeting reconvened after July 7 adjournment due to lack of quorum; 12.1% of shares represented.

## SEC filing metadata
- accession: 0001178913-25-002378
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2025-07-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891325002378/0001178913-25-002378-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891325002378/zk2533438.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-002378
- JSON: https://secwatch.observer/filing/0001178913-25-002378.json
- Plain text: https://secwatch.observer/filing/0001178913-25-002378.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.